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and is considered a heterogeneous diagnostic category [1]. Using gene expression profiling,
two major molecular subtypes termed germinal centre B-cell-like (GCB) DLBCL and acti-
vated B-cell-like (ABC) DLBCL can be distinguished [2]. Their gene expression profiles sug-
gest that they arise from B-cells at different stages of differentiation. The GCB DLBCLs
appear to originate from germinal centre B-cells, whereas the ABC DLBCLs may arise from
post-germinal-centre B-cells that are in transition to being differentiated into plasma cells.
Intriguingly, these two subtypes differ not only with respect to the expression of thousands
of genes, but also utilise different oncogenic pathways and have significantly different sur-
vival rates following therapy [3,4]. ABC DLBCLs are characterised by inferior survival com-
pared with GCB DLBCL patients when treated with a combined approach of the anti-CD20
antibody rituximab and CHOP chemotherapy [5].
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these entities lead to the identification of a variety of poten-
tially novel therapeutic targets for the treatment of affected
patients. ABC DLBCLs are characterised by constitutive activa-
tion of the oncogenic nuclear factor-jB (NF-jB) pathway,
which promotes cell proliferation and differentiation and
suppresses apoptosis [6]. NF-jB signaling is mediated by a
family of transcription factors that are normally kept inactive
in the cytoplasm by binding to inhibitory IjB proteins. The
constitutive activation of NF-jB in ABC DLBCL is caused in
the vast majority of cases by somatically acquired mutations
that affect positive (CARD11, CD79B and MYD88) and negative
(TNFAIP3) NF-jB regulators [7–10]. Inhibition of NF-jB was
toxic to preclinical models of ABC DLBCL [6]. Therefore, tar-
geting the NF-jB pathway seems to be an attractive therapeu-
tic approach. Such a strategy was taken by Dunleavy and
colleagues in a recent phase II study in which the efficacy of
bortezomib was investigated in DLBCL [11]. Preclinical data
suggest that bortezomib inhibits NF-jB by blocking IjBj
degradation. The efficacy of bortezomib in combination with
chemotherapy was evaluated in relapsed/refractory ABC and
GCB DLBCL patients [11]. Interestingly, the response rates
were significantly higher in ABC compared with GCB DLBCL,
and even more importantly, patients with ABC DLBCL had a
significantly superior overall survival. These results poten-tially suggest that inhibition of NF-jB might be a promising
approach in ABC DLBCL. This hypothesis was further sup-
ported by recently presented data on the efficacy of the Bru-
ton agammaglobulinemia tyrosine kinase (BTK) inhibitor
ibrutinib [12]. BTK plays an important role in activating NF-
jB following B-cell receptor stimulation. Using this inhibitor,
impressive response rates in relapsed and refractory ABC
DLBCL could be achieved. Collectively, these data indicate
that inhibition of the oncogenic NF-jB pathway might be a fu-
ture option to overcome the adverse prognosis of patients af-
fected by ABC DLBCL.
While patients with GCB DLBCL are characterised by supe-
rior prognosis compared with ABC DLBCL [5], a substantial
proportion of GCB DLBCL patients are not cured by standard
treatment. GCB DLBCLs frequently express the transcriptional
repressor BCL-6 that plays an important role in the germinal
centre reaction. BCL-6 therefore might represent a novel
target for GCB DLBCLs. In preclinical models, specific BCL-6
inhibitors showed impressive efficacy [13,14]. GCB DLBCLs
are furthermore frequently characterised by deregulation of
the phosphatidylinositol 3-kinase (PI3K)/AKT signaling path-
way [4]. The PI3K signaling cascade is initiated with the phos-
phorylation of phophatidylinositol 4,5-bisphosphate (PIP2) to
phophatidylinositol 3,4,5-trisphosphate (PIP3), resulting in
cellular processes such as proliferation, cell survival and cell
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 2 6 2 –2 6 3 263growth. Various PI3K inhibitors are currently being evaluated
in different cancer types and might represent a promising
therapeutic approach in GCB DLBCL.
In summary, ABC and GCB DLBCL represent molecular
subtypes that are dependent on different oncogenic signaling
pathways. In clinical reality this biological diversity is still
insufficiently taken into account. Efforts to distinguish these
entities using gene expression profiling or next-generation
sequencing will pave the way to more specific and less toxic
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